Founded in 1947, Landanger is a family-owned group with a prestigious heritage in the surgical sector, marked by major innovations such as the "Corail" hip prosthesis, still one of the most widely implanted in the world. Following the acquisition of its orthopedic business by Johnson & Johnson in 1997, the Landanger Group then focused on the development of surgical instrumentation.

It develops, produces and markets its products in France and abroad with the same vision of innovation and excellence as in its early days. Already a national leader, Landanger is pursuing an ambitious international development strategy, with distribution in over 70 countries, including the United States.

Faced with the specialization of surgical markets and the increasingly specific expectations of healthcare establishments, the Landanger group is developing a range of general and specialty instrumentation through a brand strategy such as Delacroix-Chevalier, world-renowned for its range of cardiovascular and thoracic instruments.

The Landanger Group's growth is driven by dynamic markets on all continents, stimulated by the increasing number of surgeries, the ageing population in many developed countries, the specialization of surgical techniques and the Group's innovations. Over the past five years, the Group has achieved strong, steady growth, boosting sales by almost 40% to reach 40 million euros in 2024.

The Crédit Agricole Group and BNP Paribas Développement are joining forces with Management with the ambition of becoming a European leader by continuing solid organic growth and implementing an ambitious external growth strategy, both in Europe and the United States.
 
Thibaut Cussey, Chairman of the Landanger Group, comments: "Our long-term commitment and dedication is the only model for creating value for our customers, which gives our business a great deal of meaning."

Cédric Fontaine, Managing Partner, and Mathilde Martel, Investment Director at IDIA Capital Investissement, commented: "We are delighted to join forces with the Landanger Group's management team in this ambitious new stage of its development. The group's fundamental values, its committed management, its recognized expertise and its international reputation were decisive factors in our decision to support it in the realization of its growth project. We are also enthusiastic about taking part in its innovation drive, aimed at strengthening its position in a demanding market subject to stringent regulatory constraints".

Michel Allemand, Investment Director, and Guillaume Danzelle, Investment Director, BNP Paribas Développement, commented: "We are delighted to be supporting the growth of the Landanger group, a market leader and emblematic company of the Prothesis Valley in Haute Marne. This transaction will enable the Landanger group to strengthen its market share in France and accelerate its export development."

Antoine Vigneron and Dorothée Chatain, Partners at 21 Invest France add: "We are delighted to have supported the Landanger Group in its growth project over the past five years. Our initial primary LBO was aimed at making a transition with the management team and consolidating the group's leading position in France and internationally through exports, objectives we successfully achieved. This new capital operation will enable Landanger to continue to grow and strengthen its reputation."